These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 26700063)
1. Prospective audit with adjunctive perampanel: Preliminary observations in focal epilepsy. Brodie MJ; Stephen LJ Epilepsy Behav; 2016 Jan; 54():100-3. PubMed ID: 26700063 [TBL] [Abstract][Full Text] [Related]
2. Adjunctive lacosamide in clinical practice: sodium blockade with a difference? Stephen LJ; Kelly K; Parker P; Brodie MJ Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421 [TBL] [Abstract][Full Text] [Related]
3. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies. Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508. Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON). Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147 [TBL] [Abstract][Full Text] [Related]
10. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Gidal BE; Ferry J; Majid O; Hussein Z Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853 [TBL] [Abstract][Full Text] [Related]
11. Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy. Moraes JS; Hepworth G; Ignatiadis S; Dharan A; Carne R; Seneviratne U; Cook MJ; D'Souza WJ Epilepsy Behav; 2020 Mar; 104(Pt A):106883. PubMed ID: 32045874 [TBL] [Abstract][Full Text] [Related]
12. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis. Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y; Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663 [TBL] [Abstract][Full Text] [Related]
13. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures. Tyrlikova I; Brazdil M; Rektor I; Tyrlik M Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703 [No Abstract] [Full Text] [Related]
14. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. French JA; Krauss GL; Biton V; Squillacote D; Yang H; Laurenza A; Kumar D; Rogawski MA Neurology; 2012 Aug; 79(6):589-96. PubMed ID: 22843280 [TBL] [Abstract][Full Text] [Related]
15. Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic. Stephen L; Brodie MJ Epilepsy Behav; 2021 Mar; 116():107746. PubMed ID: 33517200 [TBL] [Abstract][Full Text] [Related]
16. Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience. Juhl S; Rubboli G Acta Neurol Scand; 2016 Nov; 134(5):374-377. PubMed ID: 26763771 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies. Steinhoff BJ; Patten A; Williams B; Malhotra M Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276 [TBL] [Abstract][Full Text] [Related]
18. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080 [TBL] [Abstract][Full Text] [Related]
19. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy. Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534 [TBL] [Abstract][Full Text] [Related]
20. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]